Min Sun

Min Sun practices at UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania.

Min Sun's NPI, 1811961121, was assigned on February 14, 2006. Min Sun holds Pennsylvania license MD420448.

Min Sun's primary practice is UPMC Magee-Womens Hospital, at 300 Halket St, Pittsburgh, PA 15213 in Allegheny County. The practice phone is (412) 432-5500.

Min Sun's primary practice is UPMC Magee-Womens Hospital in Pittsburgh, Pennsylvania. The medical group on file is UPMC Hillman Cancer Center. Dmand AI also links Min Sun to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Min Sun practices. Vendor and product names are available with a free account.

Hematology and oncology is Min Sun's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Min Sun is licensed in Pennsylvania.

CMS data shows 67 Medicare services from Min Sun across 2 procedure codes in 2024, for 63 Medicare patients. Medicare paid $3,498 for them. Every service was in an office.

CMS counts 63 Medicare patients who saw Min Sun in 2024. The largest group is 65 to 74, with 25 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Min Sun's median patient age at 78, with 67% women.

In 2024, Min Sun wrote 472 Medicare Part D claims for 125 patients. 83% of them were for generic drugs. CMS names the drug for 343 of them, across 9 drugs with 11 or more claims each, at $316,392 in total drug cost. In 2023, CMS named 629 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 65 out of 100 for Min Sun for performance year 2024, reported as part of a group.

Dmand AI links 54 papers to Min Sun, published from 2011 to 2025. 2021 was the busiest year, with 8. The most frequent topics are Acute Kidney Injury, Breast Neoplasms and Cell Line, Tumor. Min Sun has published most often in Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. Min Sun's most frequent co-authors are Michael Dylan Greicius, MD, Jules Henry Sumkin, DO and Carmen Joseph Allegra, MD.

Dmand AI links Min Sun to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Breast Neoplasms, Prostatic Neoplasms and Breast Diseases.

CMS Open Payments shows 22 general payments to Min Sun from 14 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Bristol-Myers Squibb Company paid the most, $488.